Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS-866DM Phase 3 Comparative Study (ORIENT)
jRCT2080220027Phase 3
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of olmesartan medoxomil + azelnidipine in hypertension (HTN) and chronic kidney disease (CKD), sponsored by Daiichi Sankyo Co., Ltd.
02
Drugs
olmesartan medoxomil + azelnidipine
03
Conditions
hypertension (HTN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2080220027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220027.